chemmart, page-5

Check blackmores revenue of last year and compare it with a research company holding not even 2 mil on the bank.


I'm exhausted to listen to these comparisons.
If you invest in a company with such low cash reserves attempting to launch a product, coming out of 7 years of no income period trying to reenter the market, it is utter nonsense to compare them with well established companies which have 50 times the cash reserves at their disposal.


PNO has outlined in it's shareholder update that TV commercials, radio addresses etc will be part of the marketing campaign, but we obviously do not have the money to realise such promises until the CR is concluded.

What will bring a bright future to PNO is not a successful Thermalife launch, the revenue from Thermalife domestically will always be modest, it will be a license deal for Tripeptofen and we have gotten a lot closer to such a deal with the latest patent approval for Tripeptofen here in Australia and an announcement of OBJ to develop their own pain patch. This has a strong likelihood to be related to Tripeptofen and changes our outlook dramatically when developed.